NANO
vs
D
DAX Index
NANO
Over the past 12 months, NANO has significantly outperformed DAX Index, delivering a return of +526% compared to the DAX Index's +22% growth.
Stocks Performance
NANO vs DAX Index
Performance Gap
NANO vs DAX Index
Performance By Year
NANO vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nanobiotix SA
Glance View
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.